Antiangiogenic Agent |
Arsenic trioxide |
Trisenox® |
Cephalon, Inc. |
Lenalidomide |
Revlimid® |
Celgene Corporation |
Thalidomide |
Thalomid® |
Celgene Corporation |
Antimetabolite |
Azacitidine |
Vidaza® |
Celgene Corporation |
Clofarabine |
Clolar® |
Genzyme Corporation |
Decitabine |
Dacogen® |
MGI Pharma, Inc. |
Nelarabine |
Arranon® |
GlaxoSmithKline |
Pemetrexed |
Alimta® |
Eli Lilly & Company |
Growth Factors |
Pegfilgrastim |
Neulasta® |
Amgen, Inc. |
Palifermin |
Kepivance® |
Amgen, Inc. |
Miscellaneous Agent |
Bortezomib |
Velcade® |
Millennium Pharmaceuticals, Inc. |
Ixabepilone |
Ixempra™ |
Bristol-Myers Squibb Co. |
Paclitaxel Protein-Bound Particles; Albumin-Bound |
Abraxane® |
Abraxis Oncology |
Vorinostat |
Zolinza® |
Merck & Co., Inc. |
Monoclonal Antibody (Unconjugated) |
Alemtuzumab |
Campath® |
Bayer Pharmaceuticals Corporation |
Bevacizumab |
Avastin® |
Genentech, Inc. |
Cetuximab |
Erbitux® |
ImClone Systems, Inc. & Bristol-Myers Squibb Co. |
Eculizumab |
Soliris™ |
Alexion Pharmaceuticals, Inc. |
Gemtuzumab ozogamicin |
Mylotarg® |
Pfizer, Inc. |
Panitumumab |
Vectibix™ |
Amgen, Inc. |
Trastuzumab |
Herceptin® |
Genentech, Inc. |
Radioimmunoconjugate |
Capromab pendetide |
ProstaScint® |
EUSA Pharma |
Tositumomab and Iodine131I Tositumomab |
Bexxar® |
GlaxoSmithKline |
Ibritumomab tiuxetan |
Zevalin® |
Biogen Idec, Inc. |
Targeted Therapy |
Dasatinib |
Sprycel® tablets |
Bristol-Myers Squibb Co. |
Erlotinib |
Tarceva® tablets |
OSI Pharmaceuticals, Inc. & Genentech, Inc. |
Lapatinib |
Tykerb® |
GlaxoSmithKline |
Nilotinib |
Tasigna® |
Novartis Pharmaceuticals Corporation |
Sorafenib |
Nexavar® |
Bayer Pharmaceuticals Corporation |
Sunitinib |
Sutent® |
Pfizer, Inc. |
Temsirolimus |
Torisel™ |
Pfizer, Inc. |